Advertisement

Der Hautarzt

, Volume 69, Issue 8, pp 674–680 | Cite as

Initial nicht erkannte De-novo-Psoriasis getriggert durch Nivolumab bei metastasiertem Zungengrundkarzinom

  • S. Troyanova-Slavkova
  • L. Eickenscheidt
  • K. Dumann
  • L. Kowalzick
Kasuistiken

Zusammenfassung

Nivolumab ist ein monoklonaler Antikörper, der an den PD-1-Rezeptor auf T‑Zellen bindet und die Interaktion mit den Liganden PD-L1 und PD-L2 auf Krebszellen hemmt. Dadurch hat Nivolumab immunstimulierende Eigenschaften. Zu den bekannten Nebenwirkungen dieser Therapie gehören Hautausschlag, Müdigkeit, Dysfunktion der Schilddrüse und Kolitis. Diese werden durch die immunregulatorischen Mechanismen des Medikaments erklärt. Hier berichten wir über den Fall eines 58-jährigen Patienten mit metastasiertem Zungengrundkarzinom, der unter einer Therapie mit Nivolumab eine de novo getriggerte Psoriasis entwickelt hat. Der Patient wurde monatelang mit der Diagnose einer generalisierten Mykose erfolglos behandelt. Dieser Fall hebt hervor, wie wichtig es ist, auch auf unerwartete kutane Nebenwirkungen einer Therapie mit immunstimulierenden Checkpoint-Inhibitoren zu achten.

Schlüsselwörter

PD-1-Blockade Immunstimulation Checkpoint-Inhibitoren Nebenwirkungen Monoklonaler Antikörper 

Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma

Abstract

Nivolumab is a monoclonal antibody that binds to the PD-1 receptor on T cells and inhibits the interaction with the PD-L1 and PD-L2 ligands on cancer cells. Thus, nivolumab has immunostimulatory properties. The known side effects of this therapy include fatigue, skin rash, dysfunction of the thyroid gland and colitis, which are explained by the immunoregulatory mechanisms of the drug. Here we report on the case of a 58-year-old man with metastatic base of tongue carcinoma who developed de novo psoriasis triggered by nivolumab. The patient was treated for months with the diagnosis of a generalized mycosis. This case highlights the importance of vigilance for unexpected cutaneous side effects during immune stimulating therapy with checkpoint inhibitors.

Keywords

PD-1 blockade Immunostimulation Checkpoint inhibitors Side effects Monoclonal antibodies 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Troyanova-Slavkova, L. Eickenscheidt, K. Dumann und L. Kowalzick geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Literatur

  1. 1.
    Anforth R, Blumetti TC, Clements A et al (2013) Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol 169:1310–1313CrossRefPubMedGoogle Scholar
  2. 2.
    Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35:169–178CrossRefPubMedGoogle Scholar
  3. 3.
    Elosua-Gonzales MD, Pampin-Franco A et al (2017) A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. Dermatol Online J 23(8):19Google Scholar
  4. 4.
    Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jeudy G, Pahm-Ledard A, Perol M et al (2016) Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol.  https://doi.org/10.1111/jdv.14011 PubMedCrossRefGoogle Scholar
  6. 6.
    Jin HT, Ahmed R, Okazaki T (2011) Role of PD-1 in regulating T‑cell immunity. Curr Top Microbiol Immunol 350:17–37PubMedGoogle Scholar
  7. 7.
    Jour G, Glitza IC, Ellis RM et al (2016) Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43:688–696CrossRefPubMedGoogle Scholar
  8. 8.
    Kato Y, Otsuka A, Miyachi Y, Kabashima K (2016) Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 30:e89–91CrossRefPubMedGoogle Scholar
  9. 9.
    Khunger M, Calabrese C, Kontzias A, Velcheti V (2017) To treat or not to treat: role of immunotherapy in patients with concomitant diagnosis of advanced-stage non-small cell lung cancer and psoriasis. J Thorac Oncol 12:e147–9CrossRefPubMedGoogle Scholar
  10. 10.
    von Kieseritzky K (2017) Kutane Nebenwirkungen der Immuntherapie. Hautnah Dermatologie 33(3):54Google Scholar
  11. 11.
    Kim JH, Choi YJ, Lee BH et al (2016) Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1‑high T cells. J Allergy Clin Immunol 137:1466–1476CrossRefPubMedGoogle Scholar
  12. 12.
    Kubota K, Kamijima Y, Sato T et al (2015) Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 5:e6450CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Law-Ping-Man S, Martin A, Briens E et al (2016) Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford) 5:2087–2089CrossRefGoogle Scholar
  14. 14.
    Lynde CW, Poulin Y, Vender R et al (2014) Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 71:141–150CrossRefPubMedGoogle Scholar
  15. 15.
    Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T (2016) Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 96:259–260CrossRefPubMedGoogle Scholar
  16. 16.
    Nonomura Y, Otsuka A, Ohtsuka M (2017) ADAMTSL5 is upregulated in melanoma tissues in patients with idiopatic psoriasis vulagris induced by nivolumab. J Eur Acad Dermatol Venereol 31:e100–101CrossRefPubMedGoogle Scholar
  17. 17.
    Okiyama N, Tanaka R (2017) Varied immuno-related adverse events induced by immune-check point inhibitors—Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6. Nihon Rinsho Meneki Gakkai Kaishi 40:95–101CrossRefPubMedGoogle Scholar
  18. 18.
    Phadke SD, Ghabour R, Swick BL et al (2016) Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease. J Investig Med High Impact Case Rep 4:2324709616674316PubMedPubMedCentralGoogle Scholar
  19. 19.
    Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ (2014) Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153(1):145–152.  https://doi.org/10.1016/j.clim.2014.04.010 CrossRefPubMedGoogle Scholar
  20. 20.
    Peled M, Strazza M, Azoulay-Alfaguter I, Mor A (2015) Analysis of programmed death-1 in patients with psoriatic arthritis. Inflammation 38(4):1573–1580.  https://doi.org/10.1007/s10753-015-0132-2 CrossRefPubMedGoogle Scholar
  21. 21.
    Ruiz-Bañobre J, Abdulkader I, Anido U et al (2017) Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. Acta Pathol Microbiol Immunol Scand 125:259–263CrossRefGoogle Scholar
  22. 22.
    Rounds A, Kolesar J (2015) Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm 72:1851–1855CrossRefPubMedGoogle Scholar
  23. 23.
    Sahuquillo-Torralba A, Ballester-Sanchez R et al (2016) Pembrolizumab: a new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr 107:264–266CrossRefPubMedGoogle Scholar
  24. 24.
    Seebacher C, Korting HC, Abeck D et al (2005) Tinea der freien Haut. J Dtsch Dermatol Ges 3:921–926CrossRefGoogle Scholar
  25. 25.
    Sibaud V, Meyer N, Lamant L et al (2016) Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254–263CrossRefPubMedGoogle Scholar
  26. 26.
    Sundar R, Cho BC, Brahmer JR, Soo RA (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7:85–96CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021–1034CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773–781CrossRefPubMedGoogle Scholar
  29. 29.
    Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • S. Troyanova-Slavkova
    • 1
  • L. Eickenscheidt
    • 1
  • K. Dumann
    • 2
  • L. Kowalzick
    • 1
  1. 1.Klinik für Hautkrankheiten und AllergologieHELIOS Vogtland-Klinikum Plauen GmbHPlauenDeutschland
  2. 2.Dermatohistopathologie, Klinik für Dermatologie, Venerologie und AllergologieUniversitätsklinikum Leipzig AöRLeipzigDeutschland

Personalised recommendations